text: Zacks: Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) Receives Average Recommendation of "Strong Buy" from Analysts | Daily Political
  Pieris Pharmaceuticals Inc. - Get News & Ratings Daily
  Enter your email address below to get the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. with our FREE daily email newsletter:
  Tiffany & Co. (TIF) Given a $75.00 Price Target by Bank of America Corp. Analysts	Adeptus Health Inc. (ADPT) Rating Reiterated by JMP Securities	Jefferies Group Downgrades Drax Group PLC (DRXGY) to Underperform	Carriage Services Inc. (CSV) PT Raised to $32.00 at Barrington Research	Cowen and Company Analysts Give Skechers USA Inc. (SKX) a $24.00 Price Target	Analysts Offer Predictions for Virgin America Inc's Q3 2016 Earnings (VA)	Equities Analysts Offer Predictions for Rovi Corp.'s Q3 2016 Earnings (TIVO)	Copart Inc. (CPRT) PT Set at $61.00 by Stephens	Q3 2016 EPS Estimates for Franco Nevada Corp Raised by Raymond James Financial (FNV)	Character Group plc (CCT) Insider Acquires £19,996.95 in Stock	Porter,Angus Acquires 5,814 Shares of McColl's Retail Group PLC (MCLS) Stock	Honey,Matt Purchases 200,000 Shares of 7Digital Group PLC (7DIG) Stock	Insider Buying: Compass Group plc (CPG) Insider Buys £90,646 in Stock	Wells Fargo & Co. (WFC) Rating Reiterated by Raymond James Financial Inc.	Moffett Nathanson Reaffirms Buy Rating for Alphabet Inc. (GOOG)	Brokerages Expect Fresh Del Monte Produce Inc. (NYSE:FDP) to Post $0.54 Earnings Per Share	Park City Group Inc. (PCYG) Earns "Buy" Rating from Arden Partners Ltd	Qualcomm Inc. (QCOM) Raised to "Strong-Buy" at Vetr Inc.	The St. Joe Co. (NYSE:JOE) Receives Average Rating of "Hold" from Analysts	Zacks: Regis Corp. (NYSE:RGS) Given Consensus Recommendation of "Hold" by Analysts	Zacks: Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) Receives Average Recommendation of "Strong Buy" from Analysts	September 22nd, 2016 - 0 comments - Filed Under -
  by Stacy Sanders	Filed Under: Finance - Zacks Consensus Ratings	Tweet
  Shares of Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) have been assigned an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation. Brokerages have set a 1-year consensus target price of $8.00 for the company and are forecasting that the company will post ($0.13) earnings per share for the current quarter, according to Zacks. Zacks has also given Pieris Pharmaceuticals an industry rank of 91 out of 265 based on the ratings given to related companies. Separately, Roth Capital reiterated a "buy" rating and set a $6.00 target price on shares of Pieris Pharmaceuticals in a research report on Friday, August 5th.
  A number of large investors have recently modified their holdings of the company. BlackRock Fund Advisors bought a new stake in shares of Pieris Pharmaceuticals during the second quarter worth approximately $113,000. Frontier Wealth Management LLC bought a new stake in shares of Pieris Pharmaceuticals during the second quarter worth approximately $137,000. Sabby Management LLC raised its stake in shares of Pieris Pharmaceuticals by 132.7% in the first quarter. Sabby Management LLC now owns 175,000 shares of the company's stock worth $333,000 after buying an additional 99,792 shares in the last quarter. BVF Inc. IL bought a new stake in shares of Pieris Pharmaceuticals during the second quarter worth approximately $389,000. Finally, Lombard Odier Asset Management USA Corp raised its stake in shares of Pieris Pharmaceuticals by 20.3% in the second quarter. Lombard Odier Asset Management USA Corp now owns 3,166,915 shares of the company's stock worth $5,099,000 after buying an additional 533,965 shares in the last quarter. 45.79% of the stock is currently owned by hedge funds and other institutional investors. Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) opened at 1.67 on Tuesday. The company has a 50 day moving average of $1.63 and a 200-day moving average of $1.79. The company's market capitalization is $71.91 million. Pieris Pharmaceuticals has a 12-month low of $1.26 and a 12-month high of $3.08. Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings data on Wednesday, August 10th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.01. Pieris Pharmaceuticals had a negative net margin of 346.01% and a negative return on equity of 52.21%. The company earned $1.07 million during the quarter. On average, equities analysts anticipate that Pieris Pharmaceuticals will post ($0.55) EPS for the current fiscal year. Pieris Pharmaceuticals Company Profile
  Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
  Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)
  Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.